LivaNova PLC announced the FDA granted premarket approval (PMA) for the aura 6000 System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA)…. read more.
The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has granted a marketing authorisation on on 20 February 2026 to to Insmed Netherlands B.V. for brensocatib (Brinsupri) to… read more.
Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased… read more.
Untreated obstructive sleep apnoea may be costing the UK and US economies billions of pounds/dollars in lost productivity every year, with a considerable proportion of working age adults… read more.
New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also… read more.
A universal respiratory syncytial virus (RSV) immunization program using Beyfortus (nirsevimab) was associated with a statistically significant reduction in RSV-related hospitalizations in the second RSV season among infants… read more.
In short-skulled (brachycephalic) dogs, a very flat face, collapsing nostrils, and a plump physique are associated with difficulty breathing, with Pekingeses and Japanese Chins at especially high risk,… read more.
GSK announced that China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab) as add-on maintenance treatment of adult patients with inadequately controlled COPD characterised by raised blood… read more.
ARS Pharmaceuticals, Inc. announced that five poster presentations, one healthcare professional (HCP) case report, plus two late breakers from partners at ALK-Abelló A/S (ALK) centered on neffy, will… read more.
GSK plc announced that its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, has been approved by the European Commission (EC) for use in adults aged 18 years… read more.
GSK plc announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment… read more.
Researchers from Hiroshima University in Japan and collaborating institutions have found that adults with asthma who experience symptoms of depression have elevated blood levels of a protein called… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
